Company news

Share this article:
AstraZeneca posted a third quarter sales increase of 3%, to 7.8 billion, according to a company report released today. Emerging markets contributed $1.1 billion – an 18% growth – to the bottom line. In China specifically, the company saw a 35% increase in sales. Crestor profited from its atherosclerosis indication, and US sales of the drug increased by 23%, marking the only branded statin to gain market share in the US this year, according to a company statement. “AstraZeneca has delivered a robust set of results that deliver on our performance commitments despite an increasingly challenging environment for the pharmaceutical sector and business in general,” said David Brennan, CEO, in the report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.